Anticancer drug targets: growth factors and growth factor signaling
Open Access
- 1 January 2000
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 105 (1), 9-13
- https://doi.org/10.1172/jci9084
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.1999
- Effect of SB 203580 on the activity of c-Raf in vitro and in vivoOncogene, 1999
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999
- Variation Among Cell Types in the Signaling Pathways by which IGF-I Stimulates Specific Cellular Responses*Hormone and Metabolic Research, 1999
- Radiosensitization and apoptosisOncogene, 1998
- Analogs of StaurosporineGeneral Pharmacology: The Vascular System, 1998
- Increasing Complexity of the Ras Signaling PathwayJournal of Biological Chemistry, 1998
- ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENTJournal of Immunotherapy, 1997
- Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine KinasesJournal of Medicinal Chemistry, 1997
- FUNCTION AND REGULATION OF RASAnnual Review of Biochemistry, 1993